PATENT CLAIM ANALYSIS

Application Number: 16080068
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["514", "359000"]

Abstract:
The present invention provides the use of compounds which selectively block the Nav1.1 subtype of voltage-gated sodium (Nav) channels, whose role in nociception and pain has been unexplored. The present invention demonstrates that Nav1.1-expressing fibers are modality specific nociceptors: their activation elicits robust pain behaviors without neurogenic inflammation and produces profound hypersensitivity to mechanical, but not thermal, stimuli. In the gut, high-threshold mechanosensitive fibers also express Nav1.1 and show enhanced toxin sensitivity in a model of irritable bowel syndrome. The present invention provides an unexpected role for Nav1.1 in regulating the excitability of sensory nerve fibers that underlie mechanical pain, and provides methods of screening for other peptides and small molecules that can modulate Nav1.1 channels and their use in treatment of neurological disorders.

Claim (Index 15):
The method of  claim 14 , wherein the one or more additional biologically active agents comprise enzymes, receptor antagonists or agonists, hormones and antibodies, autonomic agents, such as anticholinergics, antimuscarinic anticholinergics, ergot alkaloids, parasympathomimetics, cholinergic agonist parasympathomimetics, cholinesterase inhibitor parasympathomimetics, sympatholytics, a-blocker sympatholytics, sympatholytics, sympathomimetics, adrenergic agonist sympathomimetics, intravenous anesthetics, barbiturate intravenous anesthetics, benzodiazepine intravenous anesthetics, opiate agonist intravenous anesthetics, skeletal muscle relaxants, neuromuscular blocker skeletal muscle relaxants, reverse neuromuscular blocker skeletal muscle relaxants, neurological agents, anticonvulsants, barbiturate anticonvulsants, benzodiazepine anticonvulsants, anti-migraine agents, anti-parkinsonian agents, anti-vertigo agents, opiate agonists, and opiate antagonists; psychotropic agents, antidepressants, heterocyclic antidepressants, monoamine oxidase inhibitors, selective serotonin re-uptake inhibitors, tricyclic antidepressants, antimanics, anti-psychotics, phenothiazine antipsychotics, anxiolytics, sedatives, hypnotics, barbiturate sedatives, benzodiazepine anxiolytics, sedatives, and hypnotics, and psychostimulants.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 96.0
- Lexical Diversity: 1.51111
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12930978', '13507928', '11155262', '11749814', '10071380']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7581214771196699
- 35 USC 102 Novelty (BERT): 0.4821456674272406
- Combined Prediction Score: 0.730523896150427
- Mean Citation Score: 174.12164
- Max Citation Score: 185.72151
- Similarity Product: 136.94724364255427

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test